Stock On Watch: Could iCAD Inc Change Direction After Achieving Yearly Low?

Stock On Watch: Could iCAD Inc Change Direction After Achieving Yearly Low?

The stock of iCAD Inc (NASDAQ:ICAD) hit a new 52-week low and has $2.95 target or 11.00% below today’s $3.31 share price. The 9 months bearish chart indicates high risk for the $52.78M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $2.95 price target is reached, the company will be worth $5.81 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 20,211 shares traded hands. iCAD Inc (NASDAQ:ICAD) has declined 34.24% since April 1, 2016 and is downtrending. It has underperformed by 35.45% the S&P500.

According to Zacks Investment Research, “Icad, Inc. designs, engineers, develops and manufactures digital image scanners, densitometers, film digitizers and related software for applications in the graphic arts, medical imaging and life sciences markets. The Company sells its products throughout the world through various distributors, resellers, systems integrators and OEM’s.”

More important recent iCAD Inc (NASDAQ:ICAD) news were published by: Marketwatch.com which released: “icad Inc.” on November 01, 2009, also Quotes.Wsj.com published article titled: “News icad Inc.ICAD”, Prnewswire.com published: “iCAD Announces Breakthrough Technology For Use With Digital Breast …” on March 02, 2016. More interesting news about iCAD Inc (NASDAQ:ICAD) was released by: Businesswire.com and their article: “VuCOMP Announces Sale of M-Vu® Breast Density Software to iCAD, Inc.” with publication date: April 28, 2015.

ICAD Company Profile

iCAD, Inc., incorporated on February 24, 1984, is a well-known provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Firm provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) imaging. The Firm operates in two divisions: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Firm sells its products throughout the world through its direct sales organization, as well as through various original equipment maker (OEM) partners, distributors and resellers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment